|
1
|
Chevallier N, Corcoran CM, Lennon C, et
al: ETO protein of t(8;21) AML is a corepressor for Bcl-6 B-cell
lymphoma oncoprotein. Blood. 103:1454–1463. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rowley JD: Molecular genetics in acute
leukemia. Leukemia. 14:513–517. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Maiques-Diaz A, Chou FS, Wunderlich M, et
al: Chromatin modifications induced by the AML1-ETO fusion protein
reversibly silence its genomic targets through AML1 and Sp1 binding
motifs. Leukemia. 26:1329–1337. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Klampfer L, Zhang J, Zelenetz AO, Uchida H
and Nimer SD: The AML1/ETO fusion protein activates transcription
of BCL-2. Proc Natl Acad Sci USA. 93:14059–14064. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pabst T, Mueller BU, Harakawa N, et al:
AML1-ETO downregulates the granulocytic differentiation factor
C/EBPalpha in t(8;21) myeloid leukemia. Nat Med. 7:444–451. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Linggi B, Muller-Tidow C, van de Locht L,
et al: The t(8;21) fusion protein, AML1 ETO, specifically represses
the transcription of the p14(ARF) tumor suppressor in acute myeloid
leukemia. Nat Med. 8:743–750. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kelly PN and Strasser A: The role of Bcl-2
and its pro-survival relatives in tumourigenesis and cancer
therapy. Cell Death Differ. 18:1414–1424. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Krug U, Ganser A and Koeffler HP: Tumor
suppressor genes in normal and malignant hematopoiesis. Oncogene.
21:3475–3495. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ho PA, Alonzo TA, Gerbing RB, et al:
Prevalence and prognostic implications of CEBPA mutations in
pediatric acute myeloid leukemia (AML): a report from the
Children’s Oncology Group. Blood. 113:6558–6566. 2009.PubMed/NCBI
|
|
10
|
Zhang DE, Hetherington CJ, Meyers S, et
al: CCAAT enhancer-binding protein (C/EBP) and AML1 (CBF alpha2)
synergistically activate the macrophage colony-stimulating factor
receptor promoter. Mol Cell Biol. 16:1231–1240. 1996.
|
|
11
|
Sherr CJ and Weber JD: The ARF/p53
pathway. Curr Opin Genet Dev. 10:94–99. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kamijo T, Zindy F, Roussel MF, et al:
Tumor suppression at the mouse INK4a locus mediated by the
alternative reading frame product p19ARF. Cell. 91:649–659. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kohzaki H, Ito K, Huang G, Wee HJ,
Murakami Y and Ito Y: Block of granulocytic differentiation of
32Dcl3 cells by AML1/ETO(MTG8) but not by highly expressed Bcl-2.
Oncogene. 18:4055–4062. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shikami M, Miwa H, Nishii K, et al: Low
BCL-2 expression in acute leukemia with t(8;21) chromosomal
abnormality. Leukemia. 13:358–368. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Banker DE, Radich J, Becker A, et al: The
t(8;21) translocation is not consistently associated with high
Bcl-2 expression in de novo acute myeloid leukemias of adults. Clin
Cancer Res. 4:3051–3062. 1998.PubMed/NCBI
|
|
16
|
Burel SA, Harakawa N, Zhou L, Pabst T,
Tenen DG and Zhang DE: Dichotomy of AML1-ETO functions: growth
arrest versus block of differentiation. Mol Cell Biol.
21:5577–5590. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ruas M and Peters G: The p16INK4a/CDKN2A
tumor suppressor and its relatives. Biochim Biophys Acta.
1378:F115–F177. 1998.PubMed/NCBI
|
|
18
|
Taniguchi T, Chikatsu N, Takahashi S, et
al: Expression of p16INK4A and p14ARF in hematological
malignancies. Leukemia. 13:1760–1769. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hiebert SW, Reed-Inderbitzin EF, Amann J,
Irvin B, Durst K and Linggi B: The t(8;21) fusion protein contacts
co-repressors and histone deacetylases to repress the transcription
of the p14ARF tumor suppressor. Blood Cells Mol Dis.
30:177–183. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lu Y, Xu YB, Yuan TT, et al: Inducible
expression of AML1-ETO fusion protein endows leukemic cells with
susceptibility to extrinsic and intrinsic apoptosis. Leukemia.
20:987–993. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fazi F, Zardo G, Gelmetti V, et al:
Heterochromatic gene repression of the retinoic acid pathway in
acute myeloid leukemia. Blood. 109:4432–4440. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Eberharter A and Becker PB: Histone
acetylation: a switch between repressive and permissive chromatin.
Second in review series on chromatin dynamics. EMBO Rep. 3:224–229.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kouzarides T: Histone methylation in
transcriptional control. Curr Opin Genet Dev. 12:198–209. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jones PA and Baylin SB: The epigenomics of
cancer. Cell. 128:683–692. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sharma S, Kelly TK and Jones PA:
Epigenetics in cancer. Carcinogenesis. 31:27–36. 2010. View Article : Google Scholar
|
|
26
|
Tada Y, Brena RM, Hackanson B, Morrison C,
Otterson GA and Plass C: Epigenetic modulation of tumor suppressor
CCAAT/enhancer binding protein alpha activity in lung cancer. J
Natl Cancer Inst. 98:396–406. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bennett KL, Hackanson B, Smith LT, et al:
Tumor suppressor activity of CCAAT/enhancer binding protein alpha
is epigenetically down-regulated in head and neck squamous cell
carcinoma. Cancer Res. 67:4657–4664. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hackanson B, Bennett KL, Brena RM, et al:
Epigenetic modification of CCAAT/enhancer binding protein alpha
expression in acute myeloid leukemia. Cancer Res. 68:3142–3151.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wouters BJ, Jordà MA, Keeshan K, et al:
Distinct gene expression profiles of acute myeloid/T-lymphoid
leukemia with silenced CEBPA and mutations in NOTCH1. Blood.
110:3706–3714. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kiefer MC, Brauer MJ, Powers VC, et al:
Modulation of apoptosis by the widely distributed Bcl-2 homologue
Bak. Nature. 374:736–739. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hanada M, Delia D, Aiello A, Stadtmauer E
and Reed JC: bcl-2 gene hypomethylation and high-level expression
in B-cell chronic lymphocytic leukemia. Blood. 82:1820–1828.
1993.PubMed/NCBI
|
|
32
|
Friedrich MG, Weisenberger DJ, Cheng JC,
et al: Detection of methylated apoptosis-associated genes in urine
sediments of bladder cancer patients. Clin Cancer Res.
10:7457–7465. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Esteller M, Tortola S, Toyota M, et al:
Hypermethylation-associated inactivation of p14(ARF) is independent
of p16(INK4a) methylation and p53 mutational status. Cancer Res.
60:129–133. 2000.PubMed/NCBI
|
|
34
|
Benanti JA, Wang ML, Myers HE, Robinson
KL, Grandori C and Galloway DA: Epigenetic down-regulation of ARF
expression is a selection step in immortalization of human
fibroblasts by c-Myc. Mol Cancer Res. 5:1181–1189. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hollenbach PW, Nguyen AN, Brady H, et al:
A comparison of azacitidine and decitabine activities in acute
myeloid leukemia cell lines. PLoS One. 5:e90012010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Buchi F, Spinelli E, Masala E, et al:
Proteomic analysis identifies differentially expressed proteins in
AML1/ETO acute myeloid leukemia cells treated with DNMT inhibitors
azacitidine and decitabine. Leuk Res. 36:607–618. 2012. View Article : Google Scholar
|
|
37
|
Zapotocky M, Mejstrikova E, Smetana K,
Stary J, Trka J and Starkova J: Valproic acid triggers
differentiation and apoptosis in AML1/ETO-positive leukemic cells
specifically. Cancer Lett. 319:144–153. 2012. View Article : Google Scholar : PubMed/NCBI
|
